Shopping Cart

You have 0 items in your cart
    You are currently here:

    Mouse Anti-Human VEGFR1-14/Flt1-14 (peptide), soluble NEW

    Size:
    100 µg
    Price:
    € 250
    Formulation:
    Monoclonal Antibody ; lyophilized
    Clone/AB feature:
    (#180F3B4)
    Isotype:
    IgG1
    Catalog Number:
    101-M29
    Synonyms:
    vascular endothelial growth factor receptor-1; FLT1; VEGF receptor 1;
    Application:
    ELISA, WB
    Antigen:
    uniquie C terminal peptide of sFlt1-14
    Stability:
    The lyophilized antibody is stable at room temperature for up to 1 month. The reconstituted antibody is stable for at least two weeks at 2-8 °C. Frozen aliquots are stable for at least 6 months when stored at -20 °C.
    Reconstitution:
    Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 1.0 mg/ml.
    Description:
    A human-specific splicing variant of vascular endothelial growth factor (VEGF) receptor 1 (Flt1) was discovered, producing a soluble receptor (designated sFlt1-14) that is qualitatively different from the previously described soluble receptor (sFlt1) and functioning as a potent VEGF inhibitor. sFlt1-14 is generated in a cell type-specific fashion, primarily in non-endothelial cells. Notably, in vascular smooth muscle cells, all Flt1 messenger RNA is converted to sFlt1-14, whereas endothelial cells of the same human vessel express sFlt1. sFlt1-14 expression by vascular smooth muscle cells is dynamically regulated as evidenced by its upregulation on coculture with endothelial cells or by direct exposure to VEGF. Increased production of soluble VEGF receptors during pregnancy is entirely attributable to induced expression of placental sFlt1-14 starting by the end of the first trimester. Expression is dramatically elevated in the placenta of women with preeclampsia, specifically induced in abnormal clusters of degenerative syncytiotrophoblasts known as syncytial knots, where it may undergo further messenger RNA editing. sFlt1-14 is the predominant VEGF-inhibiting protein produced by the preeclamptic placenta, accumulates in the circulation, and hence is capable of neutralizing VEGF in distant organs affected in preeclampsia. Together, these findings revealed a new natural VEGF inhibitor that has evolved in humans, possibly to protect non-endothelial cells from adverse VEGF signaling. Furthermore, the study uncovered the identity of a VEGF-blocking protein implicated in preeclampsia.
    NCBI Gene ID:
    2321
    Uniprot:
    P17948-3
    PDF Download: